Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.

TSX:SVA - Post by User

Sernova Corp > LifeSci Communications

<< Previous

Bullboard Posts

Next >>

Comment by BioTeckon May 18, 2022 3:06pm

106 Views

Post# 34693239

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:LifeSci Communications

So you think if we hit 1.57 that becomes an average? Lol, I don't even know why I waste my time. Time to take a math class and get that mercury out of your mouth. You don't reckon they'd settle on 1.60 or 1.50 instead of 1.57 which happens to be the closing price the day before the news release?

Mercuryfilling1 wrote: "Says right in the NR that it wasn't based on an average price but based on price at close."

Au contraire, Bio...it doesn't say anything about the price at close. It just says $1.57. You do realize that on Feb. 7 and April 25 we hit $1.57 as well. That sounds like an average to me. You may have lived and breathed this "work" for years but it sounds to me like you're getting a bit wheezy.

From the NR:
Specifically, concurrently with the entering into the collaboration agreement, Evotec acquired a total of 12,944,904 common shares at a price of CAD $1.57 per share for gross proceeds to Sernova of $20,323,500.